Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01849770 · ClinicalTrials.gov registry record · Phase 2
Mexiletine in Sporadic Amyotrophic Lateral Sclerosis (SALS)
A Phase 2 study, sponsored by University of Washington.
- Completed
- Registry status
- Phase 2
- Development phase
- 75
- Enrollment target
NCT01849770 is a Phase 2 study that has completed, run by University of Washington. The registered enrollment target is 75 participants.
The verdict
NCT01849770, a Phase 2 study, has completed, sponsored by University of Washington.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 75 participants
- Enrollment target
Study Summary
The purpose of this research is to find out if mexiletine is safe and effective in people with Amyotrophic Lateral Sclerosis (ALS). In this trial, participants will be taking either 300 milligrams per day of mexiletine, 900 milligrams per day of mexiletine or placebo (non-active study drug). The safety and efficacy of these doses will be compared to see if one dose is better than the other.
Interventions
- DRUG Placebo
- DRUG Mexiletine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 75 participants |
| Start Date | 2013-07 |
| Est. Completion | 2014-08 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01849770
The ClinicalTrials.gov registry entry for NCT01849770 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 75 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Washington, which has 1,048 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01849770 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01849770 about?
NCT01849770 is a clinical study titled "Mexiletine in Sporadic Amyotrophic Lateral Sclerosis (SALS)". The purpose of this research is to find out if mexiletine is safe and effective in people with Amyotrophic Lateral Sclerosis (ALS). In this trial, participants will be taking either 300 milligrams per day of mexiletine, 900 milligrams per day of mexiletine or placebo (non-active study drug). The saf...
What is the current status of trial NCT01849770?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 75 participants. The study started on 2013-07. Estimated completion is 2014-08.
What interventions are being tested in trial NCT01849770?
The interventions under investigation include: Placebo (DRUG), Mexiletine (DRUG).
Who is sponsoring clinical trial NCT01849770?
This trial is sponsored by University of Washington, which has 1,048 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.